dihexa for high blood pressure Peptide Therapy Dihexa · Disguised Alpha

1 2 Journal of Applied Physiology

BPC-157, promoted for gut healing and injury recovery, TB-500, marketed for muscle repair and performance, and MOTS-C, associated with metabolism and longevity, have attracted enormous consumer demand without any of the large-scale clinical trials required for standard FDA drug approval

LIFT-AD Phase 2/3 Failure The larger LIFT-AD trial fails both primary and key secondary endpoints, raising questions about the clinical viability of fosgonimeton

Cagrilintide has no boxed warning because it has no approved label, not because its long-term safety has been demonstrated

As of March 2026, availability may still vary by state

The committee also voted in favor of MOTS-C and TB-500